Aclaris Therapeutics Inc (NASDAQ:ACRS) has a beta value of 0.45 and has seen 1.2 million shares traded in the last trading session. The company, currently valued at $197.49M, closed the last trade at $1.83 per share which meant it gained $0.01 on the day or 0.55% during that session. The ACRS stock price is -182.51% off its 52-week high price of $5.17 and 48.09% above the 52-week low of $0.95.
The consensus among analysts is that Aclaris Therapeutics Inc (ACRS) is Buy stock at the moment, with a recommendation rating of 1.29. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Sporting 0.55% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ACRS stock price touched $1.83 or saw a rise of 12.44%. Year-to-date, Aclaris Therapeutics Inc shares have moved -26.21%, while the 5-day performance has seen it change -8.04%. Over the past 30 days, the shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) have changed -28.79%.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 73.86% from current levels. The projected low price target is $3.0 while the price target rests at a high of $8.0. In that case, then, we find that the current price level is -337.16% off the targeted high while a plunge would see the stock gain -63.93% from current levels.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
The company’s shares have gained 56.41% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 15.24% over the past 5 years. Earnings growth for 2025 is a modest 65.79% while over the next 5 years, the company’s earnings are expected to increase by 21.87%.
ACRS Dividends
Aclaris Therapeutics Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
The top two institutional holders are BML CAPITAL MANAGEMENT, LLC with over 12.99 million shares worth more than $14.29 million. As of 2024-06-30, BML CAPITAL MANAGEMENT, LLC held 18.2184% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 4.69 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.16 million and represent 6.5952% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 1.96% shares in the company for having 2.12 shares of worth $3.87 million while later fund manager owns 820.73 shares of worth $1.5 million as of Sep 30, 2024 , which makes it owner of about 0.76% of company’s outstanding stock.
